jcon wrote, "$8.5bn minimum acq price is still about 10x money from here at a baseline."
$8.5 billion divided by 100 million shares is $85 per share.
And Kelly was talking about two breakthrough designations.
I don't think he meant they wanted to sell. But if they did, would $170 a share ease your pain a bit?
More amazing, maybe, is the idea that having numerous possible blockbusters in one drug would mean that the company would NEVER have to begin at the beginning in testing, with Phase I safety tests. Indications would be low-hanging fruit on an abundant tree.